UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 81,774 Shares of Exact Sciences Co. (NASDAQ:EXAS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 6.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,421,671 shares of the medical research company's stock after acquiring an additional 81,774 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.77% of Exact Sciences worth $79,884,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital World Investors boosted its position in shares of Exact Sciences by 10.7% in the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after purchasing an additional 1,696,321 shares during the period. Price T Rowe Associates Inc. MD raised its position in Exact Sciences by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock worth $323,669,000 after acquiring an additional 2,462,165 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Exact Sciences by 25.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock worth $239,922,000 after buying an additional 876,985 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Exact Sciences by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company's stock worth $175,165,000 after acquiring an additional 16,828 shares during the period. Finally, Spyglass Capital Management LLC increased its position in shares of Exact Sciences by 10.2% in the fourth quarter. Spyglass Capital Management LLC now owns 1,539,436 shares of the medical research company's stock valued at $86,501,000 after buying an additional 142,343 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Stock Up 2.7%

EXAS stock traded up $1.52 during mid-day trading on Wednesday, hitting $58.08. The stock had a trading volume of 2,504,443 shares, compared to its average volume of 2,553,361. The company has a fifty day moving average of $48.05 and a 200 day moving average of $51.90. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83. The stock has a market capitalization of $10.96 billion, a price-to-earnings ratio of -10.43 and a beta of 0.92. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $706.79 million for the quarter, compared to the consensus estimate of $688.58 million. During the same period in the prior year, the business posted ($0.60) earnings per share. The business's quarterly revenue was up 10.9% on a year-over-year basis. On average, equities analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

EXAS has been the subject of several analyst reports. Evercore ISI upped their target price on Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Mizuho began coverage on shares of Exact Sciences in a research note on Thursday, April 10th. They issued an "outperform" rating and a $60.00 target price on the stock. Guggenheim restated a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a research note on Friday, April 11th. Royal Bank of Canada raised their target price on Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Finally, Scotiabank increased their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and an average price target of $70.90.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.